RYTM News and Press, Rhythm Pharmaceuticals Inc. From 08/03/20

Rhythm Pharmaceuticals (NASDAQ: RYTM ) : Q2 GAAP EPS of -$0.71 beats by $0.12 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Appointed David Meeker, M.D., as President and Chief Executive Officer – -- FDA granted rare pediatric disease designations for setmelanotide for the treatment of POMC and LEPR deficiency obesities -- -- Submitted MAA to EMA for setmelanotide in POMC and LEPR deficiency ...

BOSTON, July 27, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced the appointment of Joseph Shulman as the Com...

Rhythm Pharmaceuticals ( RYTM +0.8% ) appoints  David Meeker,  the company's chairman as the President and CEO, effective immediately. More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., the Chairman of Rhy...

-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing an...

The FDA has granted Rare Pediatric Disease Designatio n to Rhythm Pharmaceuticals' (NASDAQ: RYTM ) setmelanotide for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. More news on: Rhythm Pharmaceuticals, Inc., Healthcare s...

-- Company also announces positive data from eight supplemental patients, including four pediatric patients, enrolled in pivotal Phase 3 clinical trials; all achieved primary endpoint of 10 percent weight loss -- -- Setmelanotide was well-tolerated in long-term extension study with co...

BOSTON, July 01, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration (...

Rhythm Pharmaceuticals Reports Positive Phase 2 Data for Setmelanotide Rhythm Pharmaceuticals Inc. ( RYTM ) announced interim data from its Phase 2 study of Setmelanotide. Under this trial, healthy obese people were administered the weekly formulation of the drug candidate. The trial wa...